Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
2002 2
2003 2
2007 2
2008 3
2009 4
2010 5
2011 7
2012 10
2013 9
2014 10
2015 8
2016 12
2017 14
2018 14
2019 17
2020 10
2021 21
2022 12
2023 13
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, Michel L, Edan G, de Seze J, Kremer L, Bigaut K, Vukusic S, Mathey G, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Collongues N, Kerbrat A; OFSEP Investigators. Jouvenot G, et al. Among authors: clavelou p. JAMA Neurol. 2024 Mar 25:e240395. doi: 10.1001/jamaneurol.2024.0395. Online ahead of print. JAMA Neurol. 2024. PMID: 38526462
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.
Benallegue N, Rollot F, Wiertlewski S, Casey R, Debouverie M, Kerbrat A, De Seze J, Ciron J, Ruet A, Labauge P, Maillart E, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Heinzlef O, Pelletier J, Thouvenot E, Al Khedr A, Bourre B, Casez O, Cabre P, Wahab A, Magy L, Vukusic S, Laplaud DA; OFSEP (Observatoire Français de la Sclérose en Plaques) Investigators. Benallegue N, et al. Among authors: clavelou p. JAMA Neurol. 2024 Mar 1;81(3):273-282. doi: 10.1001/jamaneurol.2023.5566. JAMA Neurol. 2024. PMID: 38345791 Free PMC article.
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.
Jeantin L, Januel E, Labauge P, Maillart E, de Seze J, Zéphir H, Pelletier J, Kerschen P, Biotti D, Heinzlef O, Guilloton L, Bensa C, Théaudin M, Vukusic S, Casez O, Maurousset A, Laplaud D, Berger E, Lebrun-Frenay C, Bourre B, Branger P, Stankoff B, Clavelou P, Thouvenot E, Manchon E, Moreau T, Sellal F, Zedet M, Papeix C, Louapre C. Jeantin L, et al. Among authors: clavelou p. Mult Scler. 2024 Mar;30(3):381-395. doi: 10.1177/13524585231218149. Epub 2024 Jan 21. Mult Scler. 2024. PMID: 38247113
Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
Rollot F, Uhry Z, Dantony E, Vukusic S, Debouverie M, Le Page E, Ciron J, Ruet A, De Sèze J, Zéphir H, Labauge P, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Clavelou P, Pelletier J, Thouvenot E, Heinzlef O, Camdessanche JP, Fauvernier M, Remontet L, Leray E. Rollot F, et al. Among authors: clavelou p. Neurology. 2023 Dec 12;101(24):e2483-e2496. doi: 10.1212/WNL.0000000000207925. Epub 2023 Oct 12. Neurology. 2023. PMID: 37827849
Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial.
Lebrun-Frénay C, Siva A, Sormani MP, Landes-Chateau C, Mondot L, Bovis F, Vermersch P, Papeix C, Thouvenot E, Labauge P, Durand-Dubief F, Efendi H, Le Page E, Terzi M, Derache N, Bourre B, Hoepner R, Karabudak R, De Seze J, Ciron J, Clavelou P, Wiertlewski S, Turan OF, Yucear N, Cohen M, Azevedo C, Kantarci OH, Okuda DT, Pelletier D; TERIS Study Group. Lebrun-Frénay C, et al. Among authors: clavelou p. JAMA Neurol. 2023 Oct 1;80(10):1080-1088. doi: 10.1001/jamaneurol.2023.2815. JAMA Neurol. 2023. PMID: 37603328 Free article. Clinical Trial.
Development and Validation of a Postprocedural Model to Predict Outcome After Endovascular Treatment for Ischemic Stroke.
Chalos V, Venema E, Mulder MJHL, Roozenbeek B, Steyerberg EW, Wermer MJH, Lycklama À Nijeholt GJ, van der Worp HB, Goyal M, Campbell BCV, Muir KW, Guillemin F, Bracard S, White P, Dávalos A, Jovin TG, Hill MD, Mitchell PJ, Demchuk AM, Saver JL, van der Lugt A, Brown S, Dippel DWJ, Lingsma HF; HERMES CollaboratorsMR CLEAN Registry Investigators. Chalos V, et al. JAMA Neurol. 2023 Jul 31;80(9):940-8. doi: 10.1001/jamaneurol.2023.2392. Online ahead of print. JAMA Neurol. 2023. PMID: 37523199
150 results